This test begins with the analysis of prostate-specific antigen (PSA). If the PSA is between 2.0 and 10.0 ng/mL, then the reflex test (PHI13) will be performed.

If the initial PSA is between 2.0 and 10.0 ng/mL, then free PSA and [-2]ProPSA will be reported.

If the initial PSA is between 4.0 and 10.0 ng/mL, then the percent free PSA and prostate health index (phi) will be calculated and reported.

If the initial PSA is between 2.0 and 4.0 ng/mL, then the percent free PSA and prostate health index (phi) will not be calculated or reported.

Aids in distinguishing prostate cancer from benign prostate conditions in men with total prostate-specific antigen (PSA) concentrations in the 4 to 10 ng/mL range and digital rectal examination (DRE) findings that are not suspicious for cancer

• Specimens for testing should be drawn prior to prostate manipulations such as digital rectal examination (DRE), prostatic massage, transrectal ultrasound (TRUS), and prostatic biopsy.
• Specimens should not be collected from patients receiving therapy with high biotin (vitamin B7) doses (ie, >5 mg/day) until at least 8 hours following the last biotin administration.

Red serum vial/tube, 5 mL

1. Allow sample to clot
2. Spin
3. Transfer serum to a Screw cap transfer vial/tube (Mayo T914), labelled as serum, within 3 hours of sample collection

Screw cap transfer vial/tube (Mayo T914)

Frozen - 150 days

Immunoenzymatic Assay

See report

Medical necessity